Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProMIS Neurosciences Inc
PMN
Healthcare
Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine...
applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PMN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Nov 13, 2023 12:24pm
RE:Acumen Pharma Quarterly
Their cash on hand is more than their market cap by double... just crazy. Their stock has been driven down just like PMN. Peaked at $9.72 in July and now under $2. I'm buying both ABOS and
...more
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Nov 13, 2023 11:13am
Acumen Pharma Quarterly
Following positive Phase 1 data which started 2021-06-21, completed 2023-06-12 Initiation of Phase 2 expected to start first half of 2024. A license agreement with Halozyme to develop a subcataneous
...more
Silvercorp to Acquire Adventus, Creating a Diversified Mining Company
posted May 02, 2024 9:00am by
Adventus Mining Corp.
-
|
Under the terms of the Arrangement Agreement, each holder of the common shares of Adventus will receive 0.1015 of one Silvercorp common share in exchange for each Adventus Share at the effective time of the Transaction. The Exchange Ratio implies consideration of C$0.50 per Adventus Share ...read more
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Comment by
FarmerBetsy
on Nov 10, 2023 9:49pm
RE:Worst Performer on NASDAQ
ALL PART of the PLAN, not in Incompetence Elliott, Eugene, and Gail ! The Boston Group !!!
(95)
•••
goldtech
X
View Profile
View Bullboard History
Post by
goldtech
on Nov 10, 2023 11:20am
Worst Performer on NASDAQ
These people could not run a one hole outhouse and Gail now wins the award of being the CEO that has seen our shares go to all time lows. Great job Gail and Gene and we pay you how much for your
...more
(2)
•••
Trek1701
X
View Profile
View Bullboard History
Post by
Trek1701
on Nov 09, 2023 10:14pm
Good night
Look at the bid. Last one here remember to turn off the lights.
(97)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Nov 04, 2023 9:10am
RE:PMN vs ABOS
On a price-to-book ratio valuation: (Reference: SIMPLY WALL st) PMN: 6.3X ABOS: 0.8X G1945V
(97)
•••
G1945V
X
View Profile
View Bullboard History
Post by
G1945V
on Nov 04, 2023 6:51am
PMN vs ABOS
Putting Market Cap aside, which is a better buy? PMN: $1.78US (Nov 1, SP: $1.72) ABOS: $2.19 US (Nov 1, SP: $1.90) G1945V
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Nov 02, 2023 11:15am
Let me get this Promisneurosciences into Phase 1 correct?
Let me see if i understand this correctly? They recieve the IND filing in May after many delays which i assume points out a plan on how they can proceed into the clinic? Then psoted on July 27th
...more
(39)
•••
BottomBroker
X
View Profile
View Bullboard History
Comment by
BottomBroker
on Nov 02, 2023 9:12am
RE:WOWZERS what a Scam Artist job with Phase 1 (again more)
That was the plan all along, to test healthy individuals first. They've been saying that for many months. This comes as no surprise.
(97)
•••
G1945V
X
View Profile
View Bullboard History
Comment by
G1945V
on Nov 02, 2023 5:15am
RE:RE:WOWZERS what a Scam Artist job with Phase 1 (again more)
Surely Phase 1B would not be administered to healthy patients. G1945V
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Nov 01, 2023 9:37pm
RE:WOWZERS what a Scam Artist job with Phase 1 (again more)
Its Phase 1a- checking safety, pharmicokinetics, and CSF concentration measurement Phase 1b will focus on patients mild to moderate AD and include biomarker assessments and ARIA monitoring
(44)
•••
FarmerBetsy
X
View Profile
View Bullboard History
Post by
FarmerBetsy
on Nov 01, 2023 6:46pm
WOWZERS what a Scam Artist job with Phase 1 (again more)
Really i looked at the half proposed Phase 1 testing paper work, could have been probably done a year ago and no Alzheimers patients just HEALTY VOLUNTEERS. Looked at the Corporate update where they
...more
(82)
•••
Gbathat
X
View Profile
View Bullboard History
Comment by
Gbathat
on Oct 30, 2023 7:16pm
RE:Clinical trial start
Here we go! Thanks for sharing. Great news.
(30)
•••
bball67
X
View Profile
View Bullboard History
Post by
bball67
on Oct 30, 2023 11:41am
Clinical Trial 1A
The trial is for safety but I believe their will be spinal fluid read outs to see how much of the medication is in the spinal fluid. That will then be compared to other ALZ candidates. Based on the
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results